Advaxis Inc (NASDAQ:ADXS)

1.64
Delayed Data
As of Apr 20
 -0.05 / -2.96%
Today’s Change
1.51
Today|||52-Week Range
9.55
-42.25%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$91.4M

Company Description

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Contact Information

Advaxis, Inc.
305 College Road East
Princeton New Jersey 08540
P:(609) 452-9813
Investor Relations:
(609) 250-7575

Employees

Shareholders

Other institutional18.27%
Individual stakeholders12.50%
Mutual fund holders11.98%

Top Executives

Anthony A. LombardoCEO, Chief Business Officer & Senior VP
Christopher M. DukeChief Operating Officer & Senior Vice President
Sara BonsteinChief Financial Officer, Secretary & Executive VP
Robert G. PetitChief Scientific Officer & Executive VP
Al BluntVice President-Medical